Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Inflammation

Asthma; allergy

Oxoeicosanoid receptor 1 (OXER1; GPR170)

In vitro studies identified OXER1 antagonists that could help treat asthma and allergic diseases. Compounds that incorporated an indole scaffold and structural components of 5-oxo-eicosatetraenoic acid (ETE) antagonized OXER1 with IC50 values of about 30 nM. In cell culture, pretreatment with either of the two most potent compounds inhibited actin polymerization and chemotaxis of neutrophils and eosinophils induced by 5-oxo-ETE. Next steps include testing the antagonists in animal models of asthma or other allergic diseases.

SciBX 7(3); doi:10.1038/scibx.2014.91
Published online Jan. 23, 2014

Patent application filed covering antagonists; licensed by AmorChem Holdings Inc.; available for licensing

Gore, V. et al. J. Med. Chem.;
published online Dec. 18, 2013;
doi:10.1021/jm401292m
Contact: William S. Powell, McGill University, Montreal, Quebec, Canada
e-mail:
william.powell@mcgill.ca
Contact: Pranav Patel, Navinta LLC, Ewing, N.J.
e-mail:
pranav.patel@navinta.com
Contact: Vivek Gore, same affiliation as above
e-mail:
vivek.gore@navinta.com